Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Shin, Seung-Hwan  [Clear All Filters]
2024
Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.
2023
Park S-S, Shin S-H, Lee J-Y, Jeon Y-W, Yhang S-A, Min C-K. Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Stu. Cancers (Basel). 2023;15(19).
2022
Kim Y, Park S-S, Jeon Y-W, Yahng S-A, Shin S-H, Min C-K. Response and dynamics of renal function for transplant-eligible multiple myeloma patients who were treated with novel agent: The CAREMM-2201 study. Transplant Cell Ther. 2022.
2021
Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.
2020
Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.
Shin S-H, Park S-S, Park S, Jeon Y-W, Yoon J-H, Yahng S-A, Cho B-S, Kim Y-J, Lee S, Kim H-J, et al. Nonmyeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020.
2019
Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.
2018
Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.
2014
Lee S-E, Yoon J-H, Shin S-H, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Lee JWook, Min W-S, et al. Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biomed Res Int. 2014;2014:982504.
2013
Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Eom K-S, Kim Y-J. Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine. Blood Res. 2013;48(2):145-8.
Eom K-S, Shin S-H, Yoon J-H, Yahng S-A, Lee S-E, Cho B-S, Kim Y-J, Kim H-J, Min C-K, Kim D-W, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013.
Yoon J-H, Kim H-J, Shin S-H, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. Int J Hematol. 2013.
Lee S-E, Yoon J-H, Shin S-H, Park G, Min C-K. Skin Graft-versus-host Disease Following Autologous Stem Cell Transplantation for Multiple Myeloma. Immune Netw. 2013;13(3):107-10.